As of 2025-04-22, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (32.83) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.29 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -11429.5%.
The range of the Relative Valuation is (29.01) - (39.33) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 16.3x | 14.0x |
| Forward P/E multiples | 10.5x - 16.6x | 13.2x |
| Fair Price | (29.01) - (39.33) | (32.83) |
| Upside | -10111.5% - -13670.4% | -11429.5% |
| Date | P/E |
| 2025-04-08 | -0.10 |
| 2025-04-07 | -0.11 |
| 2025-04-04 | -0.11 |
| 2025-04-03 | -0.11 |
| 2025-04-02 | -0.13 |
| 2025-04-01 | -0.11 |
| 2025-03-31 | -0.11 |
| 2025-03-28 | -0.12 |
| 2025-03-27 | -0.12 |
| 2025-03-26 | -0.13 |
| 2025-03-25 | -0.13 |
| 2025-03-24 | -0.13 |
| 2025-03-21 | -0.12 |
| 2025-03-20 | -0.13 |
| 2025-03-19 | -0.12 |
| 2025-03-18 | -0.12 |
| 2025-03-17 | -0.12 |
| 2025-03-14 | -0.12 |
| 2025-03-13 | -0.11 |
| 2025-03-12 | -0.11 |
| 2025-03-11 | -0.11 |
| 2025-03-10 | -0.11 |
| 2025-03-07 | -0.12 |
| 2025-03-06 | -0.11 |
| 2025-03-05 | -0.11 |
| 2025-03-04 | -0.11 |
| 2025-03-03 | -0.11 |
| 2025-02-28 | -0.11 |
| 2025-02-27 | -0.11 |
| 2025-02-26 | -0.11 |
| 2025-02-25 | -0.12 |
| 2025-02-24 | -0.12 |
| 2025-02-21 | -0.12 |
| 2025-02-20 | -0.13 |
| 2025-02-19 | -0.14 |
| 2025-02-18 | -0.14 |
| 2025-02-14 | -0.14 |
| 2025-02-13 | -0.14 |
| 2025-02-12 | -0.13 |
| 2025-02-11 | -0.12 |
| 2025-02-10 | -0.13 |
| 2025-02-07 | -0.13 |
| 2025-02-06 | -0.14 |
| 2025-02-05 | -0.16 |
| 2025-02-04 | -0.14 |
| 2025-02-03 | -0.14 |
| 2025-01-31 | -0.14 |
| 2025-01-30 | -0.15 |
| 2025-01-29 | -0.15 |
| 2025-01-28 | -0.15 |